(PGNY) Progyny - Overview

Sector: Healthcare | Industry: Healthcare Plans | Exchange: NASDAQ (USA) | Market Cap: 1.381m USD | Total Return: -22.5% in 12m

Fertility Benefits, Pharmacy, Family Building, Womens Health
Total Rating 35
Safety 85
Buy Signal -0.73
Healthcare Plans
Industry Rotation: +1.6
Market Cap: 1.38B
Avg Turnover: 22.9M USD
ATR: 4.82%
Peers RS (IBD): 11.3
Risk 5d forecast
Volatility49.1%
Rel. Tail Risk-15.1%
Reward TTM
Sharpe Ratio-0.45
Alpha-40.16
Character TTM
Beta0.557
Beta Downside2.192
Drawdowns 3y
Max DD68.14%
CAGR/Max DD-0.28
EPS (Earnings per Share) EPS (Earnings per Share) of PGNY over the last years for every Quarter: "2021-03": 0.15, "2021-06": 0.19, "2021-09": 0.17, "2021-12": 0.15, "2022-03": 0.05, "2022-06": 0.09, "2022-09": 0.13, "2022-12": 0.03, "2023-03": 0.18, "2023-06": 0.15, "2023-09": 0.16, "2023-12": 0.13, "2024-03": 0.17, "2024-06": 0.17, "2024-09": 0.4, "2024-12": 0.42, "2025-03": 0.48, "2025-06": 0.19, "2025-09": 0.45, "2025-12": 0.48, "2026-03": 0,
EPS CAGR: -38.77%
EPS Trend: 52.9%
Last SUE: -1.56
Qual. Beats: 0
Revenue Revenue of PGNY over the last years for every Quarter: 2021-03: 122.133, 2021-06: 128.651, 2021-09: 122.284, 2021-12: 127.553, 2022-03: 172.217, 2022-06: 195.004, 2022-09: 205.371, 2022-12: 214.321, 2023-03: 258.394, 2023-06: 279.373, 2023-09: 280.891, 2023-12: 269.94, 2024-03: 278.078, 2024-06: 304.087, 2024-09: 286.625, 2024-12: 298.431, 2025-03: 324.038, 2025-06: 332.874, 2025-09: 313.346, 2025-12: 318.403, 2026-03: null,
Rev. CAGR: 17.81%
Rev. Trend: 90.6%
Last SUE: 0.86
Qual. Beats: 5
Warnings

choppy

Tailwinds

No distinct edge detected

Description: PGNY Progyny

Progyny, Inc. (PGNY) is a US-based benefits management company specializing in fertility, family building, and womens health solutions.

The companys core offering includes fertility benefits with a smart cycle treatment bundle, member support, and a network of fertility specialists. This business model addresses the growing demand for employer-sponsored fertility benefits.

PGNY also provides Progyny Rx, an integrated pharmacy benefits solution for fertility medications, and an assistance program for services like adoption, surrogacy, doula support, and travel reimbursement for medical services. The company operates within the Health Care Services sub-industry.

For further analysis of PGNYs financial health and market position, ValueRay offers comprehensive data and insights.

Headlines to Watch Out For
  • Employer adoption of fertility benefits drives revenue growth
  • Increased competition in benefits management impacts market share
  • Healthcare regulatory changes could affect service offerings
  • Member utilization rates influence treatment volume
  • Pharmacy benefit management margins impact profitability
Piotroski VR‑10 (Strict) 5.0
Net Income: 58.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.25 > 0.02 and ΔFCF/TA -3.20 > 1.0
NWC/Revenue: 27.11% < 20% (prev 26.05%; Δ 1.06% < -1%)
CFO/TA 0.28 > 3% & CFO 207.1m > Net Income 58.5m
Net Debt (-84.5m) to EBITDA (98.0m): -0.86 < 3
Current Ratio: 2.73 > 1.5 & < 3
Outstanding Shares: last quarter (89.5m) vs 12m ago -6.27% < -2%
Gross Margin: 23.63% > 18% (prev 0.22%; Δ 2.34k% > 0.5%)
Asset Turnover: 191.0% > 50% (prev 192.3%; Δ -1.28% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 5.85
A: 0.47 (Total Current Assets 551.8m - Total Current Liabilities 202.4m) / Total Assets 742.4m
B: 0.27 (Retained Earnings 202.8m / Total Assets 742.4m)
C: 0.14 (EBIT TTM 93.1m / Avg Total Assets 674.8m)
D: 0.90 (Book Value of Equity 203.3m / Total Liabilities 226.4m)
Altman-Z'' Score: 5.85 = AAA
Beneish M -3.32
DSRI: 0.85 (Receivables 220.3m/235.3m, Revenue 1.29b/1.17b)
GMI: 0.92 (GM 23.63% / 21.71%)
AQI: 1.06 (AQ_t 0.18 / AQ_t-1 0.17)
SGI: 1.10 (Revenue 1.29b / 1.17b)
TATA: -0.20 (NI 58.5m - CFO 207.1m) / TA 742.4m)
Beneish M-Score: -3.32 (Cap -4..+1) = AA
What is the price of PGNY shares? As of April 07, 2026, the stock is trading at USD 16.60 with a total of 1,157,200 shares traded.
Over the past week, the price has changed by -2.18%, over one month by -5.79%, over three months by -37.73% and over the past year by -22.54%.
Is PGNY a buy, sell or hold? Progyny has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold PGNY.
  • StrongBuy: 4
  • Buy: 0
  • Hold: 6
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the PGNY price?
Analysts Target Price 27.5 65.4%
Progyny (PGNY) - Fundamental Data Overview as of 03 April 2026
P/E Trailing = 25.9385
P/E Forward = 9.1241
P/S = 1.0716
P/B = 2.6933
Revenue TTM = 1.29b USD
EBIT TTM = 93.1m USD
EBITDA TTM = 98.0m USD
Long Term Debt = 27.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.73m USD (from shortTermDebt, last quarter)
Debt = 27.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -84.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.10b USD (1.38b + Debt 27.7m - CCE 310.1m)
 Interest Coverage Ratio = unknown (Ebit TTM 93.1m / Interest Expense TTM 0.0)
 EV/FCF = 5.82x (Enterprise Value 1.10b / FCF TTM 188.7m)
FCF Yield = 17.18% (FCF TTM 188.7m / Enterprise Value 1.10b)
FCF Margin = 14.64% (FCF TTM 188.7m / Revenue TTM 1.29b)
Net Margin = 4.54% (Net Income TTM 58.5m / Revenue TTM 1.29b)
Gross Margin = 23.63% ((Revenue TTM 1.29b - Cost of Revenue TTM 984.2m) / Revenue TTM)
Gross Margin QoQ = 24.15% (prev 23.24%)
Tobins Q-Ratio = 1.48 (Enterprise Value 1.10b / Total Assets 742.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 27.7m)
Taxrate = 30.07% (5.37m / 17.9m)
NOPAT = 65.1m (EBIT 93.1m * (1 - 30.07%))
Current Ratio = 2.73 (Total Current Assets 551.8m / Total Current Liabilities 202.4m)
Debt / Equity = 0.05 (Debt 27.7m / totalStockholderEquity, last quarter 516.0m)
Debt / EBITDA = -0.86 (Net Debt -84.5m / EBITDA 98.0m)
Debt / FCF = -0.45 (Net Debt -84.5m / FCF TTM 188.7m)
Total Stockholder Equity = 514.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.67% (Net Income 58.5m / Total Assets 742.4m)
RoE = 11.37% (Net Income TTM 58.5m / Total Stockholder Equity 514.6m)
RoCE = 17.16% (EBIT 93.1m / Capital Employed (Equity 514.6m + L.T.Debt 27.7m))
RoIC = 12.65% (NOPAT 65.1m / Invested Capital 514.6m)
WACC = 7.78% (E(1.38b)/V(1.41b) * Re(7.94%) + D(27.7m)/V(1.41b) * Rd(0.0%) * (1-Tc(0.30)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.77%
[DCF] Terminal Value 80.88% ; FCFF base≈182.7m ; Y1≈206.2m ; Y5≈278.9m
[DCF] Fair Price = 63.34 (EV 5.10b - Net Debt -84.5m = Equity 5.19b / Shares 81.9m; r=7.78% [WACC]; 5y FCF grow 14.98% → 3.0% )
EPS Correlation: 52.92 | EPS CAGR: -38.77% | SUE: -1.56 | # QB: 0
Revenue Correlation: 90.55 | Revenue CAGR: 17.81% | SUE: 0.86 | # QB: 5
EPS next Quarter (2026-06-30): EPS=0.48 | Chg7d=+0.004 | Chg30d=-0.021 | Revisions Net=-3 | Analysts=8
EPS current Year (2026-12-31): EPS=1.89 | Chg7d=-0.015 | Chg30d=-0.076 | Revisions Net=-5 | Growth EPS=+0.0% | Growth Revenue=+6.7%
EPS next Year (2027-12-31): EPS=2.10 | Chg7d=+0.011 | Chg30d=-0.067 | Revisions Net=-5 | Growth EPS=+11.2% | Growth Revenue=+9.7%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.1% (Discount Rate 7.9% - Earnings Yield 3.9%)
[Growth] Growth Spread = +0.3% (Analyst 4.4% - Implied 4.1%)
External Resources
Dataroma Stockcircle